Sarcopenic Obesity and Longitudinal Trajectories on Cognitive Performance and Subtle Cognitive Impairment Over 6 Years in Older Adults
Rattachement africain : es. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
BACKGROUND: Sarcopenic obesity has been suggested as a potential risk factor for cognitive decline; however, few prospective studies have been conducted to test this hypothesis. We aimed to assess the relationship between baseline sarcopenic obesity and 6-year trajectories of cognitive performance and subtle cognitive impairment in older adults. METHODS: This longitudinal study comprised 1097 older adults aged 55-75 years (mean [SD] age, 65.3 [4.9] years; 506 females [46.1%] and 591 males [53.9%]) exhibiting baseline overweight/obesity and metabolic syndrome. Baseline lower-limb muscle strength was determined by the validated 30-s Chair Stand Test. Baseline total body weight, fat mass percentage and appendicular lean mass were obtained through dual-energy x-ray absorptiometry scans. Baseline sarcopenic obesity (n = 364 [33.2%]) was subsequently defined based on the new European Society for Clinical Nutrition and Metabolism and the European Association for the Study of Obesity consensus criteria. Cognitive performance was assessed at baseline, 2, 4 and 6 years of follow-up through five composite scores derived from a comprehensive battery of eight validated neuropsychological tests, encompassing global cognitive function, general cognitive function, executive function, attention and language. Subtle cognitive impairment was defined for those z-scores 0.5 standard deviations below the mean for each cognitive performance composite score at baseline. Linear and logistic two-level mixed models including lost to follow-up participants were fitted as main analyses. Complete case analyses were additionally performed. RESULTS: After adjusting for multiple covariates, main analyses showed that, compared to older adults without sarcopenic obesity, those with sarcopenic obesity showed a higher decline in global cognitive function (between-group difference, -1.0 [95% CI, -2.2 to 0.2] after 6 years; overall p = 0.048) and general cognitive function (between-group difference, -2.5 [95% CI, -4.4 to 0.5] after 6 years; overall p = 0.028) and had a higher risk of subtle global cognitive function impairment (between-group difference, 2.3 [95% CI, 0.9 to 5.6] after 6 years; overall p = 0.038) over 6 years of follow-up. Associations remained consistent in the complete case analysis and attenuated when comparing those participants with baseline sarcopenic obesity with those only presenting sarcopenia, obesity or overweight. Of note, participants with baseline sarcopenia or obesity, compared to the absence of these conditions, showed no relationship with cognitive performance and subtle cognitive impairment over 6 years of follow-up. CONCLUSIONS: Sarcopenic obesity may be considered a potential independent risk factor for cognitive decline over the long term that warrants further evaluation in clinical settings.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Sarcopenic Obesity and Longitudinal Trajectories on Cognitive Performance and Subtle Cognitive Impairment Over 6 Years in Older Adults
- Date Crossref
- 01/12/2025
- Éditeur
- Wiley
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Instituto de Salud Carlos III CIBER Diabetes y Enfermedades Metabólicas (CIBERDEM) pays non établi dans la noticeOrganisation à but non lucratif
-
Institut de Recerca Biomèdica Catalunya Sud pays non établi dans la noticeStructure de recherche
-
Centro de Investigación Biomédica en Red pays non établi dans la noticeStructure de recherche
-
Universitat Rovira i Virgili pays non établi dans la noticeUniversité ou école supérieure
-
Navarre Institute of Health Research pays non établi dans la noticeUniversité ou école supérieure
-
Health Research Institute of the Balearic Islands Research Group on Nutritional Epidemiology & pays non établi dans la noticeStructure de recherche
-
Madrid Institute for Advanced Studies pays non établi dans la noticeUniversité ou école supérieure
-
Universidad de Valladolid pays non établi dans la noticeUniversité ou école supérieure
-
Instituto de Salud Pública de Navarra pays non établi dans la noticeÉtablissement de santé
-
Universidad Autónoma de Madrid pays non établi dans la noticeUniversité ou école supérieure
-
Universidad de Navarra pays non établi dans la noticeUniversité ou école supérieure
-
Consorci Institut D'Investigacions Biomediques August Pi I Sunyer pays non établi dans la noticeStructure de recherche
CIBER Diabetes y Enfermedades Metabólicas (CIBERDEM) — Instituto de Salud Carlos III, Institut de Recerca Biomèdica Catalunya Sud et Centro de Investigación Biomédica en Red, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.